John Maraganore joins up with Pro­QR as strate­gic ad­vi­sor; Servi­er nabs pri­or­i­ty re­view for Tib­so­vo sN­DA

Af­ter a month-long break from ad­vi­so­ry ap­point­ments, John Maraganore is once again be­ing tapped to join an­oth­er biotech.

The RNA-fo­cused start­up an­nounced Maraganore’s ap­point­ment this morn­ing, with the Al­ny­lam found­ing CEO join­ing up as a strate­gic ad­vi­sor to Pro­QR’s su­per­vi­so­ry board.

Mon­day’s move comes a few weeks af­ter the biotech’s lead can­di­date for the rare ge­net­ic eye dis­ease, Leber con­gen­i­tal amau­ro­sis, had shown no dif­fer­ence be­tween place­bo and any oth­er ef­fi­ca­cy mea­sures. Maraganore said in a state­ment that he first met Pro­QR CEO Daniel de Boer more than a decade ago through for­mer Gen­zyme CEO Hen­ri Ter­meer, be­fore his pass­ing in 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER